Gilbert Harlan Daniels, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 36 | 2023 | 2282 | 3.060 |
Why?
|
Thyrotoxicosis | 8 | 2013 | 82 | 2.490 |
Why?
|
Carcinoma, Papillary, Follicular | 5 | 2016 | 60 | 2.010 |
Why?
|
Hyperthyroidism | 7 | 2023 | 295 | 1.910 |
Why?
|
Thyroiditis | 6 | 2020 | 85 | 1.710 |
Why?
|
Iodine Radioisotopes | 11 | 2023 | 1032 | 1.550 |
Why?
|
Thyroid Nodule | 11 | 2019 | 750 | 1.550 |
Why?
|
Calcitonin | 8 | 2017 | 336 | 1.440 |
Why?
|
Graves Disease | 7 | 2023 | 242 | 1.160 |
Why?
|
Adenocarcinoma, Follicular | 6 | 2021 | 324 | 0.870 |
Why?
|
Thyroidectomy | 11 | 2013 | 879 | 0.750 |
Why?
|
Thyroid Gland | 9 | 2023 | 1173 | 0.630 |
Why?
|
Carcinoma, Papillary | 8 | 2016 | 783 | 0.630 |
Why?
|
Hypothyroidism | 6 | 2009 | 658 | 0.600 |
Why?
|
Hypoglycemic Agents | 6 | 2017 | 2872 | 0.560 |
Why?
|
Thyroxine | 8 | 2011 | 667 | 0.540 |
Why?
|
Oncogene Fusion | 2 | 2021 | 99 | 0.530 |
Why?
|
Thyrotropin | 9 | 2012 | 849 | 0.490 |
Why?
|
Glucagon-Like Peptide 1 | 3 | 2014 | 340 | 0.450 |
Why?
|
Thyroid Diseases | 3 | 2013 | 379 | 0.430 |
Why?
|
Biopsy, Fine-Needle | 7 | 2014 | 1094 | 0.420 |
Why?
|
Pyrroles | 2 | 2008 | 1146 | 0.400 |
Why?
|
Ioxaglic Acid | 1 | 2011 | 30 | 0.400 |
Why?
|
Thyroiditis, Autoimmune | 1 | 2012 | 101 | 0.400 |
Why?
|
Indoles | 2 | 2008 | 1839 | 0.350 |
Why?
|
Biopsy, Needle | 5 | 2012 | 1641 | 0.340 |
Why?
|
Terminology as Topic | 1 | 2016 | 1547 | 0.330 |
Why?
|
Practice Guidelines as Topic | 3 | 2019 | 7279 | 0.330 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 1 | 2013 | 518 | 0.320 |
Why?
|
Radiotherapy | 3 | 2013 | 1533 | 0.300 |
Why?
|
Hypopituitarism | 1 | 2008 | 254 | 0.280 |
Why?
|
Proto-Oncogene Proteins B-raf | 4 | 2021 | 2043 | 0.280 |
Why?
|
Lithium Compounds | 1 | 2008 | 225 | 0.280 |
Why?
|
Carotid Artery, Internal | 1 | 2008 | 445 | 0.270 |
Why?
|
Endocrine System Diseases | 1 | 2008 | 248 | 0.270 |
Why?
|
Ultrasonography | 5 | 2020 | 5985 | 0.260 |
Why?
|
Adenoma | 1 | 2016 | 2174 | 0.260 |
Why?
|
Arteriovenous Fistula | 1 | 2008 | 315 | 0.260 |
Why?
|
Thyroglobulin | 5 | 2014 | 114 | 0.250 |
Why?
|
Hyperprolactinemia | 2 | 2008 | 129 | 0.250 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2017 | 11725 | 0.250 |
Why?
|
Carcinoma, Neuroendocrine | 3 | 2021 | 332 | 0.240 |
Why?
|
Diabetes Complications | 1 | 2011 | 1359 | 0.230 |
Why?
|
Immunoglobulins, Thyroid-Stimulating | 2 | 2013 | 34 | 0.220 |
Why?
|
Radiation Tolerance | 2 | 2015 | 486 | 0.220 |
Why?
|
Mutation | 7 | 2021 | 29786 | 0.210 |
Why?
|
Radiopharmaceuticals | 3 | 2023 | 2645 | 0.210 |
Why?
|
Thyroiditis, Subacute | 1 | 2001 | 10 | 0.200 |
Why?
|
Humans | 73 | 2023 | 744343 | 0.200 |
Why?
|
Contrast Media | 2 | 2013 | 5300 | 0.200 |
Why?
|
Carcinoma, Medullary | 4 | 2011 | 123 | 0.190 |
Why?
|
Adenoma, Oxyphilic | 2 | 2021 | 143 | 0.190 |
Why?
|
Lithium Carbonate | 1 | 2001 | 184 | 0.190 |
Why?
|
Genetic Testing | 1 | 2013 | 3444 | 0.180 |
Why?
|
Amiodarone | 1 | 2001 | 212 | 0.170 |
Why?
|
Risperidone | 1 | 2000 | 383 | 0.160 |
Why?
|
Triiodothyronine | 3 | 2011 | 494 | 0.160 |
Why?
|
Female | 46 | 2017 | 380194 | 0.160 |
Why?
|
Middle Aged | 33 | 2017 | 213383 | 0.160 |
Why?
|
Antimanic Agents | 1 | 2001 | 522 | 0.150 |
Why?
|
DNA, Mitochondrial | 2 | 2023 | 817 | 0.150 |
Why?
|
Early Detection of Cancer | 1 | 2011 | 3086 | 0.150 |
Why?
|
Pheochromocytoma | 2 | 2005 | 337 | 0.140 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 12959 | 0.140 |
Why?
|
Male | 39 | 2017 | 350118 | 0.130 |
Why?
|
Thyroid Function Tests | 2 | 2013 | 286 | 0.130 |
Why?
|
Virus Diseases | 1 | 2001 | 711 | 0.130 |
Why?
|
Cell Differentiation | 3 | 2019 | 11483 | 0.130 |
Why?
|
Granuloma, Foreign-Body | 1 | 1995 | 45 | 0.130 |
Why?
|
Hyperplasia | 2 | 2017 | 1185 | 0.130 |
Why?
|
Thyroid Hormones | 2 | 2008 | 390 | 0.120 |
Why?
|
Amylases | 1 | 2014 | 173 | 0.120 |
Why?
|
Aged | 26 | 2016 | 163280 | 0.120 |
Why?
|
Pentagastrin | 2 | 2011 | 17 | 0.120 |
Why?
|
Polytetrafluoroethylene | 1 | 1995 | 233 | 0.120 |
Why?
|
Carcinoma | 3 | 2015 | 2375 | 0.120 |
Why?
|
Carcinoma, Renal Cell | 1 | 2008 | 3143 | 0.110 |
Why?
|
Compartment Syndromes | 1 | 1995 | 153 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 2 | 2013 | 17446 | 0.110 |
Why?
|
Adult | 26 | 2014 | 214055 | 0.110 |
Why?
|
Evidence-Based Medicine | 2 | 2019 | 3610 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2019 | 555 | 0.110 |
Why?
|
Lipase | 1 | 2014 | 314 | 0.110 |
Why?
|
Interferon-beta | 1 | 2013 | 323 | 0.100 |
Why?
|
Ferrosoferric Oxide | 1 | 2013 | 360 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1813 | 0.100 |
Why?
|
Receptors, Thyrotropin | 1 | 2011 | 45 | 0.100 |
Why?
|
Double-Blind Method | 5 | 2017 | 12026 | 0.100 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2023 | 2214 | 0.100 |
Why?
|
Receptors, Glucagon | 1 | 2011 | 92 | 0.090 |
Why?
|
Adrenal Glands | 1 | 2013 | 546 | 0.090 |
Why?
|
Multiple Endocrine Neoplasia Type 2a | 2 | 2011 | 44 | 0.090 |
Why?
|
Iodine | 1 | 2013 | 286 | 0.090 |
Why?
|
Tumor Burden | 1 | 2016 | 1915 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10943 | 0.090 |
Why?
|
Adenocarcinoma | 3 | 2020 | 6364 | 0.090 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2727 | 0.090 |
Why?
|
Neck Dissection | 1 | 2011 | 197 | 0.090 |
Why?
|
Pituitary Function Tests | 1 | 2008 | 27 | 0.090 |
Why?
|
Sensitivity and Specificity | 4 | 2013 | 14722 | 0.080 |
Why?
|
Antineoplastic Agents | 2 | 2008 | 13695 | 0.080 |
Why?
|
Obesity | 1 | 2011 | 12745 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3616 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2023 | 4253 | 0.080 |
Why?
|
Prostheses and Implants | 1 | 1995 | 1387 | 0.070 |
Why?
|
Sex Factors | 4 | 2015 | 10397 | 0.070 |
Why?
|
Linear Models | 2 | 2015 | 5952 | 0.070 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2170 | 0.070 |
Why?
|
Antipsychotic Agents | 1 | 2000 | 3057 | 0.070 |
Why?
|
Adrenal Insufficiency | 1 | 2008 | 184 | 0.070 |
Why?
|
Adipose Tissue, Brown | 1 | 2012 | 757 | 0.070 |
Why?
|
Canada | 1 | 2011 | 2065 | 0.070 |
Why?
|
SEER Program | 2 | 2014 | 1508 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4186 | 0.070 |
Why?
|
Follow-Up Studies | 5 | 2017 | 39050 | 0.070 |
Why?
|
Ultrasonography, Interventional | 1 | 2013 | 1486 | 0.070 |
Why?
|
Autoantibodies | 1 | 2013 | 2035 | 0.060 |
Why?
|
Reference Values | 3 | 2013 | 4982 | 0.060 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2007 | 224 | 0.060 |
Why?
|
Aged, 80 and over | 8 | 2014 | 57776 | 0.060 |
Why?
|
Cardiovascular Diseases | 3 | 2016 | 15165 | 0.060 |
Why?
|
History, 20th Century | 1 | 2013 | 2740 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2012 | 6895 | 0.060 |
Why?
|
Pregnancy Complications | 1 | 1999 | 2861 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2013 | 19905 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2005 | 220 | 0.060 |
Why?
|
Retrospective Studies | 9 | 2013 | 77449 | 0.060 |
Why?
|
Lipid Peroxides | 1 | 2023 | 73 | 0.060 |
Why?
|
Oxyphil Cells | 1 | 2023 | 57 | 0.060 |
Why?
|
Fermentation | 1 | 2023 | 144 | 0.060 |
Why?
|
Angiography | 1 | 2008 | 1639 | 0.060 |
Why?
|
Lymphatic Metastasis | 4 | 2012 | 2924 | 0.050 |
Why?
|
Calcium | 2 | 2013 | 5756 | 0.050 |
Why?
|
Weight Loss | 1 | 2013 | 2622 | 0.050 |
Why?
|
Treatment Outcome | 8 | 2016 | 63114 | 0.050 |
Why?
|
Quinazolines | 1 | 2008 | 1356 | 0.050 |
Why?
|
Survival Analysis | 2 | 2012 | 10252 | 0.050 |
Why?
|
Iodide Peroxidase | 1 | 2003 | 293 | 0.050 |
Why?
|
Body Mass Index | 2 | 2017 | 12720 | 0.050 |
Why?
|
Young Adult | 5 | 2014 | 56430 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2013 | 3297 | 0.050 |
Why?
|
Health Care Costs | 1 | 2014 | 3209 | 0.050 |
Why?
|
Point Mutation | 1 | 2005 | 1623 | 0.050 |
Why?
|
Phosphotransferases | 1 | 2021 | 308 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15076 | 0.050 |
Why?
|
Bone Density | 1 | 2013 | 3468 | 0.050 |
Why?
|
Osmolar Concentration | 1 | 2000 | 683 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20129 | 0.040 |
Why?
|
Vitamin D | 1 | 2013 | 3223 | 0.040 |
Why?
|
Glucocorticoids | 1 | 2008 | 2107 | 0.040 |
Why?
|
Neoplasm Staging | 2 | 2011 | 11031 | 0.040 |
Why?
|
Prolactin | 1 | 2000 | 669 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2684 | 0.040 |
Why?
|
Haploidy | 1 | 2018 | 136 | 0.040 |
Why?
|
Prognosis | 2 | 2016 | 29063 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2012 | 9239 | 0.040 |
Why?
|
Clozapine | 1 | 2000 | 498 | 0.040 |
Why?
|
Research Report | 1 | 2020 | 355 | 0.040 |
Why?
|
Chorionic Gonadotropin | 1 | 1999 | 477 | 0.040 |
Why?
|
Lymph Nodes | 2 | 2002 | 3474 | 0.040 |
Why?
|
Goiter, Nodular | 1 | 1996 | 24 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6234 | 0.030 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4851 | 0.030 |
Why?
|
Time Factors | 3 | 2012 | 40075 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3508 | 0.030 |
Why?
|
Pancreatic Neoplasms | 1 | 2013 | 5256 | 0.030 |
Why?
|
Pakistan | 1 | 1995 | 295 | 0.030 |
Why?
|
Risk | 2 | 2004 | 9687 | 0.030 |
Why?
|
Radionuclide Imaging | 1 | 1999 | 2031 | 0.030 |
Why?
|
Pregnancy | 2 | 2011 | 29144 | 0.030 |
Why?
|
United States | 6 | 2014 | 69872 | 0.030 |
Why?
|
Methimazole | 1 | 2013 | 41 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 35421 | 0.030 |
Why?
|
Propylthiouracil | 1 | 2013 | 69 | 0.030 |
Why?
|
Mass Screening | 2 | 2007 | 5255 | 0.030 |
Why?
|
Antithyroid Agents | 1 | 2013 | 70 | 0.030 |
Why?
|
Telomerase | 1 | 2018 | 730 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 311 | 0.030 |
Why?
|
Whole Body Imaging | 1 | 2014 | 280 | 0.030 |
Why?
|
Health Status | 1 | 2006 | 4034 | 0.030 |
Why?
|
Postpartum Period | 1 | 1999 | 1086 | 0.030 |
Why?
|
Barium Sulfate | 1 | 2012 | 180 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2008 | 4262 | 0.030 |
Why?
|
Iopamidol | 1 | 2012 | 191 | 0.030 |
Why?
|
Vocal Cord Paralysis | 1 | 1995 | 267 | 0.020 |
Why?
|
Neoplasms | 2 | 2017 | 21683 | 0.020 |
Why?
|
Ablation Techniques | 1 | 2013 | 249 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2001 | 6489 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2002 | 8642 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 2011 | 349 | 0.020 |
Why?
|
Pain | 2 | 2006 | 4986 | 0.020 |
Why?
|
Prevalence | 3 | 2014 | 15226 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2018 | 1941 | 0.020 |
Why?
|
Consensus | 1 | 2019 | 2959 | 0.020 |
Why?
|
Cytodiagnosis | 1 | 2013 | 435 | 0.020 |
Why?
|
Adolescent | 5 | 2014 | 85781 | 0.020 |
Why?
|
Child | 3 | 2013 | 77709 | 0.020 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2011 | 241 | 0.020 |
Why?
|
Incidental Findings | 1 | 2013 | 689 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1206 | 0.020 |
Why?
|
Fasting | 1 | 2014 | 1593 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2012 | 492 | 0.020 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2006 | 547 | 0.020 |
Why?
|
Drainage | 1 | 2013 | 1142 | 0.020 |
Why?
|
Gastrointestinal Diseases | 1 | 2016 | 1170 | 0.020 |
Why?
|
Pancreatitis | 1 | 2014 | 1092 | 0.020 |
Why?
|
Melanoma | 1 | 2006 | 5510 | 0.020 |
Why?
|
Vanilmandelic Acid | 1 | 2005 | 17 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2006 | 5686 | 0.020 |
Why?
|
Metanephrine | 1 | 2005 | 26 | 0.020 |
Why?
|
Multiple Endocrine Neoplasia | 1 | 2005 | 25 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 4445 | 0.020 |
Why?
|
Catecholamines | 1 | 2005 | 387 | 0.020 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 2005 | 768 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2010 | 1770 | 0.020 |
Why?
|
Ultrasonography, Doppler | 1 | 2007 | 458 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2007 | 11124 | 0.020 |
Why?
|
Quality of Life | 1 | 2006 | 12804 | 0.020 |
Why?
|
Preoperative Care | 1 | 2013 | 2250 | 0.020 |
Why?
|
Cohort Studies | 3 | 2014 | 40561 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 1990 | 933 | 0.010 |
Why?
|
Biopsy | 1 | 1996 | 6756 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7149 | 0.010 |
Why?
|
Codon | 1 | 2005 | 611 | 0.010 |
Why?
|
Neck | 2 | 2002 | 697 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2012 | 2016 | 0.010 |
Why?
|
Postoperative Care | 1 | 2010 | 1486 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6365 | 0.010 |
Why?
|
Risk Assessment | 3 | 2012 | 23338 | 0.010 |
Why?
|
Incidence | 2 | 2014 | 20947 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 1996 | 3507 | 0.010 |
Why?
|
Sex Distribution | 1 | 2007 | 2297 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2348 | 0.010 |
Why?
|
Age Distribution | 1 | 2007 | 2902 | 0.010 |
Why?
|
Massachusetts | 1 | 2013 | 8663 | 0.010 |
Why?
|
Length of Stay | 1 | 2013 | 6309 | 0.010 |
Why?
|
Survival Rate | 1 | 2014 | 12788 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1992 | 2245 | 0.010 |
Why?
|
Kidney | 1 | 2014 | 7186 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12245 | 0.010 |
Why?
|
Pedigree | 1 | 2005 | 4644 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 5987 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2008 | 6538 | 0.010 |
Why?
|
Logistic Models | 1 | 2011 | 13408 | 0.010 |
Why?
|
Cysts | 1 | 2002 | 678 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6622 | 0.010 |
Why?
|
Age Factors | 1 | 2012 | 18370 | 0.010 |
Why?
|
Survivors | 1 | 2006 | 2291 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2016 | 11727 | 0.010 |
Why?
|
Radiography | 1 | 2006 | 7023 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 21746 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2005 | 4803 | 0.010 |
Why?
|
Stroke | 1 | 2016 | 9981 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2007 | 11366 | 0.010 |
Why?
|
Prospective Studies | 2 | 2013 | 53288 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15295 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2008 | 15540 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1990 | 588 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1996 | 1257 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1990 | 224 | 0.010 |
Why?
|
Child, Preschool | 1 | 2011 | 41006 | 0.010 |
Why?
|
Animals | 1 | 2001 | 168757 | 0.010 |
Why?
|
Luminescent Measurements | 1 | 1990 | 405 | 0.000 |
Why?
|
Immunoassay | 1 | 1990 | 752 | 0.000 |
Why?
|